SG11201901558VA - Pth compounds with low peak-to-trough ratios - Google Patents
Pth compounds with low peak-to-trough ratiosInfo
- Publication number
- SG11201901558VA SG11201901558VA SG11201901558VA SG11201901558VA SG11201901558VA SG 11201901558V A SG11201901558V A SG 11201901558VA SG 11201901558V A SG11201901558V A SG 11201901558VA SG 11201901558V A SG11201901558V A SG 11201901558VA SG 11201901558V A SG11201901558V A SG 11201901558VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- pth
- english
- september
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Reverberation, Karaoke And Other Acoustics (AREA)
- Bipolar Transistors (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16191454 | 2016-09-29 | ||
EP17155846 | 2017-02-13 | ||
PCT/EP2017/074594 WO2018060312A1 (en) | 2016-09-29 | 2017-09-28 | Pth compounds with low peak-to-trough ratios |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901558VA true SG11201901558VA (en) | 2019-03-28 |
Family
ID=60051489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901558VA SG11201901558VA (en) | 2016-09-29 | 2017-09-28 | Pth compounds with low peak-to-trough ratios |
Country Status (25)
Country | Link |
---|---|
US (3) | US11759504B2 (es) |
EP (2) | EP4218795A3 (es) |
JP (2) | JP7085535B2 (es) |
KR (2) | KR20230170810A (es) |
CN (2) | CN117257922A (es) |
AU (1) | AU2017336251B2 (es) |
BR (1) | BR112019005793A2 (es) |
CA (1) | CA3037447A1 (es) |
DK (1) | DK3518961T3 (es) |
ES (1) | ES2943720T3 (es) |
FI (1) | FI3518961T3 (es) |
HR (1) | HRP20230383T1 (es) |
HU (1) | HUE062009T2 (es) |
IL (1) | IL265601A (es) |
LT (1) | LT3518961T (es) |
MA (1) | MA46345A (es) |
MX (1) | MX2019003182A (es) |
NZ (1) | NZ751745A (es) |
PL (1) | PL3518961T3 (es) |
RS (1) | RS64177B1 (es) |
RU (1) | RU2766959C2 (es) |
SG (1) | SG11201901558VA (es) |
SI (1) | SI3518961T1 (es) |
WO (1) | WO2018060312A1 (es) |
ZA (1) | ZA201901813B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
EP3423103A1 (en) * | 2016-03-01 | 2019-01-09 | Ascendis Pharma Bone Diseases A/S | Pth prodrugs |
CN117257922A (zh) | 2016-09-29 | 2023-12-22 | 阿森迪斯药物骨疾病股份有限公司 | 具有低峰-谷比的pth化合物 |
CN109789189B (zh) | 2016-09-29 | 2024-01-23 | 阿森迪斯药物骨疾病股份有限公司 | 控释pth化合物的剂量方案 |
JP2021516222A (ja) * | 2018-03-16 | 2021-07-01 | ザ ジェネラル ホスピタル コーポレイション | 副甲状腺ホルモンポリペプチドコンジュゲートおよびその使用方法 |
US20220088149A1 (en) | 2019-02-11 | 2022-03-24 | Ascendis Pharma Bone Diseases A/S | Liquid Pharmaceutical Formulations of PTH Conjugates |
WO2021144249A1 (en) | 2020-01-13 | 2021-07-22 | Ascendis Pharma Bone Diseases A/S | Hypoparathyroidism treatment |
IL301411A (en) | 2020-09-28 | 2023-05-01 | Ascendis Pharma Bone Diseases As | Improving the physical and mental condition of patients with hypoparathyroidism |
AU2022350937A1 (en) | 2021-09-22 | 2024-03-21 | Ascendis Pharma Bone Diseases A/S | Long-acting pth compound treatments |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744444A (en) | 1989-10-27 | 1998-04-28 | Haemopep Pharma Gmbh | HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof |
US5567439A (en) | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
MY120063A (en) | 1997-12-09 | 2005-08-30 | Lilly Co Eli | Stabilized teriparatide solutions |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
US20050124537A1 (en) | 2000-04-27 | 2005-06-09 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
WO2003064462A1 (fr) | 2002-02-01 | 2003-08-07 | Chugai Seiyaku Kabushiki Kaisha | Pth a liaison peg ou derive de pth a liaison peg |
US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
CA2843439A1 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd | Reversible pegylated drugs |
US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
KR101241862B1 (ko) | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 glp-1 유도체 |
CA2786794C (en) | 2004-03-23 | 2017-09-12 | Complex Biosystems Gmbh | Aromatic polymeric cascade prodrug linker reagent |
AU2005247369A1 (en) | 2004-05-10 | 2005-12-08 | Mdrna, Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
CN1597697A (zh) | 2004-07-19 | 2005-03-23 | 中国药科大学 | 一种人的甲状旁腺素1-34肽相关肽-Pro-Pro-[Arg11]]hPTH(1-34)-Pro-Pro |
US20060069021A1 (en) | 2004-08-13 | 2006-03-30 | Nastech Pharmaceutical Company Inc. | Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs |
EP1799759A1 (en) | 2004-08-30 | 2007-06-27 | Lunamed Inc. | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
CN1298386C (zh) | 2005-08-31 | 2007-02-07 | 上海交通大学 | 甲状旁腺激素缓释微球的制备方法 |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
US20080039775A1 (en) | 2006-03-15 | 2008-02-14 | Alza Corporation | Apparatus and Method for Transdermal Delivery of Parathyroid Hormone Agents to Prevent or Treat Osteopenia |
MX2009002859A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. |
JP5200027B2 (ja) | 2006-10-13 | 2013-05-15 | イーライ リリー アンド カンパニー | Pth受容体モジュレーターとしてのペグ化pthおよびその使用 |
US8101729B2 (en) | 2007-03-19 | 2012-01-24 | Henry Joseph Niemczyk | Pegylated amino acid derivatives and the process to synthesize the same |
EP3091075B1 (en) | 2007-04-09 | 2018-06-13 | The Board of Trustees of The University of Arkansas | Fusion proteins of collagen-binding domain and parathyroid hormone |
CN101063125A (zh) | 2007-04-17 | 2007-10-31 | 江南大学 | 人甲状旁腺激素与人血清白蛋白的融合蛋白的制备方法及产品 |
CN101970678B (zh) | 2007-06-21 | 2014-08-20 | 慕尼黑科技大学 | 具有增加的体内和/或体外稳定性的生物学活性蛋白 |
TW200922624A (en) | 2007-07-11 | 2009-06-01 | Enzon Pharmaceuticals Inc | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
EP2052736A1 (en) | 2007-10-26 | 2009-04-29 | Nycomed Danmark ApS | Parathyroid hormone formulations und uses thereof |
EP2596805B1 (en) * | 2008-02-01 | 2021-10-27 | Ascendis Pharma A/S | Prodrug comprising a drug-linker conjugate |
US9272048B2 (en) | 2008-04-29 | 2016-03-01 | Ascendis Pharma Growth Disorders Division A/S | PEGylated recombinant human growth hormone compounds |
WO2009143412A2 (en) | 2008-05-23 | 2009-11-26 | Enzon Pharmaceuticals, Inc. | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
WO2009156481A1 (en) | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
JP2012500284A (ja) | 2008-08-19 | 2012-01-05 | フェリング ベスローテン フェンノートシャップ | ペプチド性pth受容体アゴニスト |
CN102348715B (zh) | 2009-02-03 | 2017-12-08 | 阿穆尼克斯运营公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
BR112012002280B1 (pt) | 2009-07-31 | 2020-04-07 | Ascendis Pharma As | hidrogel insolúvel em água baseado em polietileno glicol biodegradável, seu processo de preparação, conjugado, composto ligado a veículo e composição farmacêutica. |
PE20120918A1 (es) | 2009-07-31 | 2012-08-14 | Sanofi Aventis Deutschland | Profarmacos que comprenden un conjugado de insulina-conector |
RU2556340C2 (ru) | 2009-07-31 | 2015-07-10 | Санофи-Авентис Дойчланд Гмбх | Композиция инсулина длительного действия |
EP2459225A1 (en) * | 2009-07-31 | 2012-06-06 | Ascendis Pharma A/S | Carrier linked pramipexole prodrugs |
EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
WO2011012723A1 (en) * | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Injectable sustained release compositions comprising a pramipexole prodrug |
ITMI20091512A1 (it) | 2009-08-28 | 2011-02-28 | Al Ma C Packaging S R L | Procedimento per il confezionamento di gruppi di contenitori per prodotti liquidi alimentari, in particolare bottiglie di acqua e/o bevande, e fardello ottenibile per mezzo di tale procedimento |
EP2485767A1 (en) | 2009-10-06 | 2012-08-15 | Ascendis Pharma A/S | Carrier linked paliperidone prodrugs |
ES2667025T3 (es) | 2009-12-15 | 2018-05-09 | Ascendis Pharma Endocrinology Division A/S | Composición seca de hormona de crecimiento unida transitoriamente a un portador de polímero |
CN102724967A (zh) | 2009-12-31 | 2012-10-10 | 安龙制药公司 | 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物 |
WO2011089215A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
US9561285B2 (en) | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
WO2011089216A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
US20110229580A1 (en) | 2010-03-22 | 2011-09-22 | Indian Institute of Technology Bombay, School of Biosciences and Bioengineering | Compositions and methods for nano-in-micro particles |
WO2011123813A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
CN103025164B (zh) | 2010-05-05 | 2017-03-08 | 普罗林科斯有限责任公司 | 从固体支撑物中药物的控制释放 |
CN103025165B (zh) | 2010-05-05 | 2016-06-08 | 普罗林科斯有限责任公司 | 自大分子共轭物的控释 |
US9492508B2 (en) | 2010-05-13 | 2016-11-15 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
CN102883734B (zh) | 2010-05-21 | 2018-01-02 | Xl-蛋白有限责任公司 | 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途 |
US8865220B2 (en) * | 2010-06-14 | 2014-10-21 | Kaohsiung Medical University | Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres |
JP5594791B2 (ja) | 2010-06-30 | 2014-09-24 | Necソリューションイノベータ株式会社 | 属性判定方法、属性判定装置、プログラム、記録媒体および属性判定システム |
US20120040320A1 (en) | 2010-08-13 | 2012-02-16 | Nadeau Daniel A | Injection Simulation Device and Methods Thereof |
EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
KR20140082649A (ko) * | 2011-08-12 | 2014-07-02 | 아센디스 파마 에이에스 | 프로스타사이클린의 서방형 조성물 |
CA2843504C (en) * | 2011-08-12 | 2020-08-25 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
CN103857413A (zh) | 2011-08-12 | 2014-06-11 | 阿森迪斯药物股份有限公司 | 载体连接的曲罗尼尔前药 |
CA2843503C (en) | 2011-08-12 | 2020-12-22 | Ulrich Hersel | Polymeric hyperbranched carrier-linked prodrugs |
AU2012296955B2 (en) * | 2011-08-12 | 2016-12-15 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
RU2014118642A (ru) | 2011-10-12 | 2015-11-20 | Асцендис Фарма Офтальмолоджи Дивижн А/С | Предотвращение и лечение глазных нарушений |
US8883862B2 (en) | 2012-01-12 | 2014-11-11 | Kaohsiung Medical University | Method for controlled release of parathyroid hormone from cross-linked hyaluronic acid hydrogel |
CA2868925C (en) | 2012-04-25 | 2020-01-21 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
US9457096B2 (en) | 2012-07-06 | 2016-10-04 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) | Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery |
WO2014033540A2 (en) | 2012-08-28 | 2014-03-06 | The Governors Of The University Of Alberta | Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods of making and using thereof |
AU2013328785B2 (en) | 2012-10-11 | 2016-07-21 | Ascendis Pharma A/S | Hydrogel prodrugs |
SG11201501914XA (en) | 2012-10-11 | 2015-05-28 | Ascendis Pharma Ophthalmology Division As | Vegf neutralizing prodrugs for the treatment of ocular conditions |
US10980860B2 (en) * | 2012-10-11 | 2021-04-20 | Ascendis Pharma A/S | Diagnosis, prevention and treatment of diseases of the joint |
EP2908845A1 (en) | 2012-10-17 | 2015-08-26 | Novo Nordisk Health Care AG | Fatty acid acylated amino acids for growth hormone delivery |
CN104884093A (zh) | 2012-12-07 | 2015-09-02 | 阿森迪斯药物股份有限公司 | 载体连接型前列腺素类前药 |
GB201303771D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticles peptide compositions |
EP2988783A1 (en) * | 2013-04-22 | 2016-03-02 | Ascendis Pharma A/S | Hydrogel-linked prodrugs releasing modified drugs |
WO2015031709A1 (en) | 2013-08-30 | 2015-03-05 | Perosphere, Inc. | Rapid acting injectable formulations comprising a peptide and a vasodilatory agent |
AU2014333954C1 (en) * | 2013-10-08 | 2020-08-27 | Ascendis Pharma A/S | Protecting group comprising a purification tag |
EP2868326A1 (en) | 2013-11-04 | 2015-05-06 | Université Pierre et Marie Curie (Paris 6) | Peptide inhibitors of TEAD/YAP-TAZ interaction |
EP3193941A1 (en) * | 2014-08-06 | 2017-07-26 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
US20170368189A1 (en) | 2015-01-09 | 2017-12-28 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
EP3423103A1 (en) | 2016-03-01 | 2019-01-09 | Ascendis Pharma Bone Diseases A/S | Pth prodrugs |
CN117257922A (zh) | 2016-09-29 | 2023-12-22 | 阿森迪斯药物骨疾病股份有限公司 | 具有低峰-谷比的pth化合物 |
JP7039574B2 (ja) | 2016-09-29 | 2022-03-22 | アセンディス ファーマ ボーン ディジージズ エー/エス | 放出制御pth化合物の漸増用量設定 |
CN109843295B (zh) | 2016-09-29 | 2022-04-05 | 阿森迪斯药物生长障碍股份有限公司 | 控释cnp激动剂的组合疗法 |
CN109789189B (zh) | 2016-09-29 | 2024-01-23 | 阿森迪斯药物骨疾病股份有限公司 | 控释pth化合物的剂量方案 |
AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
KR20210013584A (ko) | 2018-05-18 | 2021-02-04 | 아센디스 파마 본 디지즈 에이/에스 | Pth 접합체의 개시 용량 |
US20220088149A1 (en) | 2019-02-11 | 2022-03-24 | Ascendis Pharma Bone Diseases A/S | Liquid Pharmaceutical Formulations of PTH Conjugates |
WO2021144249A1 (en) | 2020-01-13 | 2021-07-22 | Ascendis Pharma Bone Diseases A/S | Hypoparathyroidism treatment |
-
2017
- 2017-09-28 CN CN202311052760.2A patent/CN117257922A/zh active Pending
- 2017-09-28 RS RS20230344A patent/RS64177B1/sr unknown
- 2017-09-28 LT LTEPPCT/EP2017/074594T patent/LT3518961T/lt unknown
- 2017-09-28 JP JP2019516692A patent/JP7085535B2/ja active Active
- 2017-09-28 EP EP23157504.4A patent/EP4218795A3/en active Pending
- 2017-09-28 NZ NZ751745A patent/NZ751745A/en unknown
- 2017-09-28 BR BR112019005793A patent/BR112019005793A2/pt unknown
- 2017-09-28 HR HRP20230383TT patent/HRP20230383T1/hr unknown
- 2017-09-28 HU HUE17781427A patent/HUE062009T2/hu unknown
- 2017-09-28 KR KR1020237041945A patent/KR20230170810A/ko active Application Filing
- 2017-09-28 ES ES17781427T patent/ES2943720T3/es active Active
- 2017-09-28 FI FIEP17781427.4T patent/FI3518961T3/fi active
- 2017-09-28 AU AU2017336251A patent/AU2017336251B2/en active Active
- 2017-09-28 EP EP17781427.4A patent/EP3518961B1/en active Active
- 2017-09-28 DK DK17781427.4T patent/DK3518961T3/da active
- 2017-09-28 MX MX2019003182A patent/MX2019003182A/es unknown
- 2017-09-28 SI SI201731350T patent/SI3518961T1/sl unknown
- 2017-09-28 WO PCT/EP2017/074594 patent/WO2018060312A1/en unknown
- 2017-09-28 MA MA046345A patent/MA46345A/fr unknown
- 2017-09-28 CA CA3037447A patent/CA3037447A1/en active Pending
- 2017-09-28 KR KR1020197012458A patent/KR102611820B1/ko active IP Right Grant
- 2017-09-28 RU RU2019112919A patent/RU2766959C2/ru active
- 2017-09-28 US US16/337,955 patent/US11759504B2/en active Active
- 2017-09-28 PL PL17781427.4T patent/PL3518961T3/pl unknown
- 2017-09-28 CN CN201780060139.7A patent/CN109789188B/zh active Active
- 2017-09-28 SG SG11201901558VA patent/SG11201901558VA/en unknown
-
2019
- 2019-03-25 IL IL265601A patent/IL265601A/en unknown
- 2019-03-25 ZA ZA2019/01813A patent/ZA201901813B/en unknown
-
2020
- 2020-08-10 US US16/989,225 patent/US20200360488A1/en not_active Abandoned
-
2022
- 2022-06-06 JP JP2022091286A patent/JP7434419B2/ja active Active
- 2022-11-08 US US18/053,701 patent/US11857603B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
SG11201408261UA (en) | Syringe | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
SG11201901576QA (en) | Dosage regimen for a controlled-release pth compound | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201804587QA (en) | Isoindole compounds | |
SG11201808686VA (en) | Synthesis of indazoles | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201908660RA (en) | N-substituted indole derivatives | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201906767XA (en) | Estrogen receptor modulators | |
SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
SG11202000494UA (en) | Drug delivery composition | |
SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
SG11201907217RA (en) | Pharmaceutical combinations for treating cancer |